論文 - 詳細
| RRC ID | 32581 |
|---|---|
| 著者 | Takahashi K, Ito Y, Morikawa M, Kobune M, Huang J, Tsukamoto M, Sasaki K, Nakamura K, Dehari H, Ikeda K, Uchida H, Hirai S, Abe T, Hamada H. |
| タイトル | Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. |
| ジャーナル | Mol Ther |
| Abstract |
In acute myocardial infarction (AMI), prognosis and mortality rate are closely related to the infarct size and the progression of postinfarction cardiac failure. Angiogenic gene therapy has presented a new approach for the treatment of AMI. Angiopoietin-1 (Ang1) is a critical angiogenic factor for vascular maturation and enhances vascular endothelial growth factor (VEGF)-induced angiogenesis in a complementary manner. We hypothesized that gene therapy using Ang1 for AMI might promote angiogenesis cooperatively with intrinsic VEGF, since high concentrations of circulating VEGF have been reported in AMI. To evaluate our hypothesis, we employed a rat AMI model and adenoviral Ang1 (HGMW-approved gene symbol ANGPT1) gene transfer to the heart. A significant increase in capillary density and reduction in infarct sizes were noted in the infarcted hearts with adenoviral Ang1 gene treatment compared with control infarcted hearts treated with saline or adenoviral vector containing the beta-galactosidase gene. Furthermore, the Ang1 group showed significantly higher cardiac performance in echocardiography (55.0% of ejection fraction, P < 0.05 vs control) than the saline or adenoviral controls (36.0 or 40.5%, respectively) 4 weeks after myocardial infarction. The adenoviral delivery of Ang1 during the acute phase of myocardial infarction would be feasible to attenuate the progression of cardiac dysfunction in the rat model. |
| 巻・号 | 8(4) |
| ページ | 584-92 |
| 公開日 | 2003-10-1 |
| DOI | 10.1016/s1525-0016(03)00230-2 |
| PII | S1525-0016(03)00230-2 |
| PMID | 14529831 |
| MeSH | Adenoviridae* Angiopoietin-1 / genetics* Angiopoietin-1 / metabolism Animals Disease Models, Animal Genetic Therapy* Genetic Vectors* Myocardial Infarction / drug therapy* Neovascularization, Physiologic / drug effects Rats Vascular Endothelial Growth Factor A / metabolism |
| IF | 8.986 |
| 引用数 | 58 |
| WOS 分野 | MEDICINE, RESEARCH & EXPERIMENTAL BIOTECHNOLOGY & APPLIED MICROBIOLOGY GENETICS & HEREDITY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 35 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| 遺伝子材料 | pCAhAng1 (RDB03963) pAxCAhAng1 (RDB05698) pWEAxCAhAng1(E)-F/RGD (RDB03972) AxCAhAng1 (RDB05697). |